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ABSTRACT 
Histamine (HA) is one of the main immediate mediators involved in allergic reactions. HA 
plasma concentration is well correlated with the severity of vascular and respiratory signs of 
anaphylaxis. Consequently, plasma quantification of HA is useful to comfort the diagnosis of 
anaphylaxis. Currently, radioimmunoassay (RIA) is the gold standard method to quantify HA 
due to its high sensitivity, but it is time consuming, implicates specific formations and 
cautions for technicians, and produces hazardous radioactive wastes. The aim of this study 
was to compare two enzymatic immunoassays (EIA) and one in-house liquid chromatography 
high-resolution mass spectrometry method (LC-HRMS) with the gold standard method for 
HA quantification in plasma samples of patients suspected of anaphylaxis reactions. Ninety-
two plasma samples were tested with the 4 methods (RIA, 2 EIA and LC-HRMS) for HA 
quantification. Fifty-eight samples displayed HA concentrations above the positive cut-off of 
10 nM evaluated by RIA, including 18 highly positive samples (> 100 nM). Our results 
showed that Immunotech® EIA and LC-HRMS concentrations were highly correlated with 
RIA values, in particular for samples with a HA concentration around the positive cut-off. In 
our hands, plasma concentrations obtained with the Demeditec Diagnostics® EIA correlated 
less with results obtained by RIA, and an underestimation of plasma HA levels led to a lack of 
sensitivity. In conclusion, this study demonstrates that Immunotech® EIA and LC-HRMS 
method could be used instead of RIA to assess plasma HA in human diagnostic use. 
ABBREVIATIONS 
EIA: enzymatic immunoassay 
HA: histamine 
LC-HRMS: liquid chromatography high resolution mass spectrometry 
RIA: radioimmunoassay 
 
Keywords: enzymatic immunoassay, histamine, mass spectrometry, radioimmunoassay
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1. INTRODUCTION 
Anaphylaxis is a potentially lethal systemic type I hypersensitivity reaction [1]. This life-
threatening emergency can lead very quickly to hypovolemia shock and cardiorespiratory 
arrest. In western countries, anaphylaxis incidence is estimated to be comprised between 4 
and 50/100000 inhab/year with a prevalence of 0.05–2%. Emergency admission registers 
highlight a two fold increase of anaphylaxis prevalence during the last decades [2].  
After a first exposure to an allergen leading to high-affinity IgE synthesis by long-lived 
plasma cells, these IgE are predominantly found linked to the high-affinity IgE receptor 
(FcεRI) at the cell surface of mast cells and basophils. Following a second exposure to the 
same allergen, the cross-linking of the FcεRI leads to cell activation and the release within a 
few minutes of a huge amount of histamine (HA) contained in cell granules (10-5 to 10-3 
mol/L) [3, 4], as well as other preformed proinflammatory mediators [5]. HA or 2-(1H-
imidazol-4-yl) ethanamine is synthetized from L-histidine in the Golgi apparatus by the 
histidine decarboxylase [6]. Several cell types can synthetize HA in humans [7],but mast cells 
and basophils distinguish themselves by their ability to store HA in their granules, enabling a 
huge acute release of HA upon IgE cross-linking.  
The anaphylaxis diagnosis is usually retained on a body of evidence. Suspicion is made 
primarily on clinical signs [8-10]. Currently, two biological parameters are commonly used to 
strengthen the diagnosis of anaphylaxis: serum tryptase and plasma HA. HA quantification is 
useful to confirm that clinical signs result from the degranulation of mast cells and/or 
basophils [11]. Physiologically, basal plasma HA amount is very low (<10nM) [8] but can 
increase very quickly and exponentially after mast cell or basophil degranulation. 
Nevertheless, the HA protein half-life is extremely short [12]. Consequently, strict procedures 
of sampling for HA quantification are required: blood collection must be conducted within 
15-60min after the beginning of the symptoms and plasma isolation has to be performed very 
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quickly before conservation [13]. The production of highly specific monoclonal antibodies 
targeting HA is extremely challenging due to the nature of this small biogenic amine 
(M=111g.mol-1). The former quantification assays were based on the covalently binding of 
HA to a carrier protein on imidazole core or on NH2 end; nevertheless this chemical process 
was difficult to apply on plasma samples. Currently, classical HA quantification assays used 
for in vitro diagnosis (IVD) and based either on radioimmunoassay (RIA) [14] or enzymatic 
immunoassay (EIA) methods include an acylation step with NOH succinimide ester succinyl 
glycinamide, which turns HA into a bigger and more stable molecule that becomes easily 
detectable. Acylated plasma HA competes with exogenous acylated HA conjugated with a 
radioelement or an enzyme to bind a highly specific monoclonal antibody [15]. The current 
gold standard for HA quantification is RIA, it has the advantage of being highly sensitive 
[14], but requires the use of radioactive reagents implying the formation and the follow up of 
the technicians, as well as the dangerous and expensive waste management. More recently, 
two EIA kits for IVD use, both avoiding the use of radioelements, have been commercialized 
by Immunotech® and Demeditec Diagnostics®. Finally, some methods using mass 
spectrometry have been developed to quantify plasma HA [16, 17]. In particular, our team 
developed an in-house plasma HA quantification assay for diagnostic use based on high 
Resolution Accurate Mass LC-MS (LC-HRMS) technology [18]. The LC-HRMS method is 
known to be highly sensitive and specific, averts radioactivity use, and avoids the potential 
detection of the metabolites of the targeted protein.  
In this study, HA concentration was assessed in human plasma collected from patients with 
suspected anaphylactic reaction using three different methods: the gold standard RIA, the two 
commercialized EIA kits, and the in-house LC-HRMS-based method. This comparison 
reveals that Immunotech® EIA and LC-HRMS are both sensitive enough methods to be 
considered as relevant non-radioactive alternative methods to RIA. 
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2. MATERIALS AND METHODS 
2.1 Plasma samples 
Plasmas collected between February 2010 and February 2014 in routine clinical practice by 
laboratories of Angers and Rennes University Hospitals from patients following a suspected 
anaphylaxis reaction were tested for HA quantification. The Ethical Review Board in Angers 
approved this study (2015/40). Peripheral blood was collected by venipuncture in EDTA 
tubes, and plasma was separated by centrifugation at 3000g for 10min. Thereafter, plasma 
was aspirated gently while respecting a safety margin of 1cm from the buffy coat in order to 
avoid contamination by white blood cells, aliquoted and immediately frozen at -20°C. 
 
2.2 Radioimmunoassay 
HA quantification by RIA was performed following manufacturer’s instructions 
(Immunotech, Marseille, France). Briefly, immediately after thawing, HA contained in plasma 
samples was acylated. Then, plasma samples were incubated overnight within monoclonal 
antibody (mAb)-coated tubes in presence of a 125I-labeled acylated HA internal tracer. 
Following incubation, the contents of the tubes were aspirated and bound radioactivity was 
measured using a Cobra 2 auto gamma counter (Packard instrument, Meriden, CT, USA) . 
Limits of quantification given by the manufacturer were 0.2-100nM. The limit for 
pathological values is 10nM. 
 
2.3 Enzymatic immunoassays 
HA quantification by EIA was performed following manufacturers’ recommendations 
(Immunotech® and Demeditec Diagnostics®, Kiel, Germany). For both kits, samples were 
manipulated in polypropylene tubes and tested in duplicate. 
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For Immunotech® EIA, HA was acylated by a first vortex step with an acylation reagent. 
Acylated control, standard and plasma solutions were further incubated in mAb-coated wells 
in presence of alkaline phosphatase acylated HA for 2 hours at 2-8°C under shaking 
(350rpm). After incubation, wells were rinsed with a microtiter plate washer in order to 
remove non-bound components. The remaining enzymatic activity was then measured at 
405nm after the addition of a chromogenic substrate. A quadratic polynomial equation was 
used to define the standard curve; the correlation coefficient r was always >0.993 [0.987-
0.999], and the median control values were 5.561 [95% CI 5.459-5.660] nM for theoretical 
value between 5.00 and 7.40nM. Standard curve included dilutions from 1.00 to 100nM of 
HA, as recommended. Limits of quantification given by the manufacturer were 0.50-100nM.  
For Demeditec Diagnostics® EIA, HA was acylated by incubation with an acylating reagent 
for 45min at room temperature (RT) on a shaker (600rpm) and further competed with plastic-
coated HA for a precise amount of HA antibody binding sites added into the well. 
Equilibrium of the system was reached after 3 hours at RT (20-25°C) on a shaker 
(approximately 600rpm). Then, free antibody and plasma HA-antibody complexes were 
removed by washing. The antibodies conjugated with plastic-coated HA were detected by a 
peroxidase-conjugated anti-rabbit IgG using tetramethylbenzidine as substrate. The reaction 
was monitored at 450nm. A quadratic polynomial equation was used to define the standard 
curve, included standard concentrations between 4.5 and 450nM of HA, as recommended. 
The correlation coefficient r was always >0.99 [0.992-1.000]. The median control values were 
26.1nM [22.0-33.7] and 80.4nM [60.6-102.5] for theoretical values of 30.0 and 100.0nM, 
respectively. The manufacturer gave no target range of concentration for the controls. Limits 
of quantification given by the manufacturer were 6.6-76.0nM. 
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2.4 High Resolution Accurate Mass LC-MS technology 
A liquid chromatography coupled with an ultra-high resolution and accurate mass instrument 
was used to determine HA concentration. Briefly, 100μL of plasma was added to 250μL of 
de-ionized water and 100μL of internal standard Histamine-d4 (HAd4) (C/D/N isotopes, 
Quebec, Canada). Sulfosalicylic acid (50μL at 20% v/v) (Sigma-Aldrich, Saint-Louis, MO, 
USA) was added for protein precipitation. After centrifugation at 3000g for 10min at 4°C, 
200μL of supernatant were transferred to an auto-sample vial before analysis. Separation of 
the analytes was achieved on a C18 Accucore column (100 mm x 2.1, 2.6μm) (Thermo 
Scientific, San José, CA, USA) using a gradient run with solvant A (nonafluoropentanoic acid 
3mM) and solvent B (acetonitrile-formic acid 0.1:100, v/v) formic acid). The analytes were 
detected using a Q ExactiveTM (Thermo Scientific) mass spectrometer operating in positive 
electrospray ionisation. In full scan mode, the exact mass of each protonated species 
(112.0869 for HA; 116.1120 for HAd4) was extracted for quantification; one ion transition 
was monitored per compound for quantification in fragmentation mode (HA: 
112.0869>95.0607 m/z; and HAd4: 116.1120> 99.0855 m/z). The calibration curve for HA in 
plasma was linear from 1 to 100nM. 
 
2.5 Statistical analysis 
Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive 
value (NPV) of EIA and LC-HRMS were calculated and compared to RIA. A threshold of 
10nM was used, because 10nM is considered the classical admitted limit for pathological 
values [8], and corresponds to the cut-offs given by manufacturers for RIA and EIA kits. 
Then, the analyses were restricted to the samples with HA measures comprised within the 
quantification limits of the two methods. HA concentrations measured by LC-HRMS, and 
Immunotech® and Demeditec Diagnostics® EIA were compared using Pearson correlation 
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coefficient with concentrations obtained with RIA. Bland-Altman tests were performed to 
evaluate the agreement of each method versus RIA. Bias and 95th limits of agreement (LOA, 
average difference ± 1.96SD of the difference) were calculated. Samples with a RIA-
measured HA concentration comprised between 1 and 20nM were further specifically 
investigated, because this range of concentrations could be delicate to interpret by the 
clinicians, and must be interpreted together with the severity of the symptoms and the results 
of additional biological tests, in order to conclude to anaphylaxis. Finally, receiver operating 
characteristic (ROC) curves were used to determine the new cut-off values for EIA 
Immunotech® and LC-HRMS methods; the optimal cut-off point being the threshold that 
maximizes the sum of the sensitivity and the specificity (Youden's index). GraphPad Prism 
5.0 (GraphPad software, San Diego, CA, USA), Excel and Stata (College Station, TX, USA) 
softwares were used. 
 
3. RESULTS AND DISCUSSION 
3.1 Cohort recruitment and HA quantification by RIA 
This study aimed to compare HA concentrations of human plasma samples from patients with 
suspected anaphylactic reaction quantified with several assays for in vitro diagnostic use. HA 
measurement for 34 samples (37%) was quantified below the threshold of 10nM by RIA, and 
was consequently considered negative in routine clinical practice. One of these 34 samples 
was quantified below 0.2nM corresponding to the RIA lower limit of detection. Fifty-eight 
samples (63%) were considered positive with HA concentration measured by RIA above 
10nM, including 18 samples with a concentration above the RIA upper limit of quantification 
of 100nM. Globally, HA concentrations of our cohort of 92 samples were well distributed 
over the quantification range of the RIA. The RIA method remains the historical gold 
standard for HA quantification in biologic fluids since several decades. Despite its high 
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sensitivity (analytical sensitivity: 0.2nM), this radioactive method displays several 
disadvantages, including the exposition risk of technicians to 125I and the management of 
radioactive wastes. Furthermore, the use of the radioactive reagents restricted to a specific 
window of radioactive decay leads to peculiar ordering of reagents, increases the delay of 
reagent shipment, and consequently expands the waiting time of results for the patient. We 
selected 3 alternative assays using 2 different methods: Immunotech® EIA, Demeditec 
Diagnostics® EIA and LC-HRMS (Table S1) [18, 19]. HA concentration values obtained by 
RIA were compared with the HA concentrations obtained with each of the other methods, 
based on a list of samples presenting a HA concentration in the detection limits of both tested 
methods. 
 
3.2 Comparison of Immunotech® EIA to RIA 
HA concentration of the 92 tested samples was evaluated with RIA and Immunotech® EIA. 
Considering all samples, sensitivity of the Immunotech® EIA method was 100% with no false 
negative, and the specificity was 59% (table 1). Indeed, 14 false positive results were obtained 
with the Immunotech® EIA method with HA quantification values comprised between 11 and 
16nM. Comparing HA concentrations measured with the 2 methods, a maximal difference of 
8.6nM for 2 samples was obtained. Finally, the positive and negative predictive values were 
81% and 100%, respectively (table 1).  
Among the 92 samples from our cohort, 91 were within the detection limits of RIA. Among 
the 91 samples, 72 (79%) were between 0.5 and 100nM, the detection limits of Immunotech® 
EIA. We therefore decided to only compare these 72 selected samples, and calculated a 
Pearson's correlation coefficient r of 0.96 (95% CI 0.94-0.98; p<0.0001) for this sample set 
(figure 1A). The Bland-Altman plot comparing Immunotech® EIA to RIA values showed an 
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estimated bias of 3.10nM (SD: 6.02nM; 95% limits of agreement: -8.69 - 14.90nM) (figure 
1B).  
Because HA concentrations between 1 and 20nM could be arduous to interpret for clinicians 
[20], a focus was made on samples displaying concentrations measured by RIA comprised in 
this range (n=47), and a Pearson's correlation coefficient of 0.88 (95% CI 0.80-0.93; 
p<0.0001) was calculated (Figure 1C). The subsequent Bland-Altman plot showed an 
estimated bias of +2.97nM (SD: 3.08nM; 95% limits of agreement: -3.07 - 9.01nM) (table 2).  
Globally, Immunotech® EIA and RIA values were well correlated even if a slight 
overestimation of HA concentration using Immunotech® EIA was observed. Of note, 
Immunotech® EIA kit has been developed by the same manufacturer and shares with the RIA 
kit most of the reagents. Essentially only the revelation step (125I-labeled histamine tracer 
versus histamine-phosphatase alkaline conjugate) is different. Interestingly, EIA methods 
avoid staff exposition to radiation hazards, are easy to perform, and do not require specifically 
trained staff, unlike RIA methods. Moreover, equipment needed is inexpensive and widely 
available.  
In conclusion, besides a slight overestimation of HA concentrations, all these observations 
support the hypothesis that EIA can be a favorable alternative to RIA, as described previously 
for other molecules like progesterone, cortisol, or infliximab [21-23]. 
 
3.3 Comparison of Demeditec Diagnostics® EIA to RIA 
For the 92 plasma samples tested, no false positive were found resulted in 100% specificity 
for Demeditec Diagnostics EIA versus RIA. Nevertheless, 20 false negative values were 
observed leading to a sensitivity of 66% (table 1). 
Among the 91 samples within the detection limits of RIA, only 23 plasma samples (25%) 
were between 6.66 and 76nM, the limits of detection of Demeditec Diagnostics® EIA, and 
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were further compared to RIA. The Pearson’s correlation coefficient r calculated for the 23 
samples was 0.45 (95% CI: 0.05-0.73; p=0.0311) (figure 2A). As shown in the Bland-Altman 
plot, HA quantification was underestimated with Demeditec Diagnostics® EIA with a mean 
difference of -17.85nM (SD: 20.16nM; 95% limits of agreement: -57.36 - 21.66nM) (figure 
2B). Finally, only 4 samples quantified between 1 and 20nM by RIA were in the limits of 
quantification of Demeditec Diagnostics® EIA kit, so it was not judicious to specifically focus 
on these samples.  
In conclusion, in our hands, the use of Demeditec Diagnostics® EIA resulted in an important 
proportion of false negative samples, which could be an obstacle for the diagnosis of 
anaphylaxis. A poor correlation with RIA values was obtained, despite excellent correlation 
coefficients obtained for the standard curves built with 5 standard dilutions (r>0.99). 
Comparing Demeditec Diagnostics® EIA, Immunotech® EIA and RIA protocols, we noticed a 
longer acylation step for Demeditec Diagnostics® EIA (45min versus an immediate acylation 
by vortexing for the 2 other assays). This could explain the important underestimation of HA 
quantification for the Demeditec Diagnostics® EIA method, because it is well known that HA 
remains stable only after acylation. 
 
3.4 Comparison of LC-HRMS to RIA 
For the 92 plasma samples tested, LC-HRMS sensitivity was 93% with 4 false negatives, and 
specificity was 100% with no false positive. The PPV and NPV were 100% and 89%, 
respectively (table 1).  
Seventy-one of the 92 tested plasma samples showed HA concentrations comprised within the 
limits of quantification of the 2 methods. The Pearson’s correlation coefficient r calculated on 
the 71 samples was 0.90 (95% CI 0.84-0.94; p<0.0001) (figure 3A). Bland-Altman plot 
showed an underestimation of the LC-HRMS method (bias: -5.52nM; SD: 10.64nM; 95% 
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limits of agreement: -26.36 - 15.33nM) (figure 3B). When considering the 46 samples with a 
HA quantification comprised between 1 and 20nM by RIA, LC-HRMS results remained 
highly correlated to those obtained using RIA (Pearson’s correlation coefficient r = 0.97; 95% 
CI: 0.95-0.98; p<0.0001) (figure 3C), and a mean difference of -1.94nM (SD: 1.26nM; 95% 
limits of agreement: -4.41 - 0.53nM) was obtained for the Bland-Altman analysis (table 2). At 
this same range, Immunotech® EIA was weakly correlated with a correlation coefficient of 
0.88, was still very sensitive, but display many false positive results that could lead to 
overdiagnosis (Figure 1C). 
In conclusion, besides a slight underestimation of HA concentrations measured by LC-
HRMS, LC-HRMS gave particularly encouraging results, as a good correlation with RIA was 
found [18].  
 
3.5 Comparison of the 3 tested assays to RIA 
The 4 tested assays display similar characteristics with respect to their lower limit of 
quantification and their quantification range, except for the Demeditec Diagnostics® EIA 
which display a lower limit of quantification (LLOQ) of 6.66nM, close to the positive 
threshold of 10nM. Our results highlight a very high sensitivity for Immunotech® EIA and 
LC-HRMS (100% and 93%, respectively), in contrast to Demeditec Diagnostics® EIA (66%). 
This latter assay showed 20 false negative among the 58 samples considered as positive with a 
threshold of 10nM. Among these 20 false negative results, RIA quantified 3 of them as having 
a concentration higher than 70nM. Demeditec Diagnostics® EIA and LC-HRMS showed a 
perfect specificity (1.00 for both), compared to RIA. A high number of false positives were 
found for Immunotech® EIA (14 out of 72 positive samples), but the mean HA concentration 
of these samples was 11.91+/-1.40nM, which represent concentrations close to the positive 
threshold of 10nM.  
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It is well known that HA is very quickly metabolized in vivo by the histamine N-
methyltransferase (HNMT) and the diamine oxydase (DAO) with a short half-life estimated at 
102 seconds (17). A degradation of HA for a specific test can be rule out, as samples for each 
assay were aliquoted and frozen simultaneously. Thawing procedure in ice was also the same 
for the 4 assays. According to the manufacturers’ data, cross-reactivity with the metabolite 
methyl histamine is estimated at 0.1% in Demeditec Diagnostics® EIA, and cross-reactivity to 
acylated methyl histamine is estimated at 0.027%, and 0.069% in Immunotech® EIA and RIA, 
respectively. LC-HRMS is the only assay that can distinguish methyl histamine from HA [16-
18]. This could explain the trend of LC-HRMS to slightly underestimate plasma HA 
concentrations in comparison to RIA. 
 
3.6 New cut-offs for Immunotech® EIA and LC-HRMS assays 
At the sight of statistical results obtained with Immunotech EIA and LC-HRMS method, we 
decided to optimize the sensitivity and specificity of these 2 assays by determining new cut-
offs. For this purpose, Ninety-two plasma samples have been used to build ROC curves in 
order to define new cut-offs for Immunotech EIA® kit and LC-HRMS method. Using the cut-
off value of 10nM of HA after quantification with RIA, 58 plasma samples were classified as 
positive (≥10nM) and 34 as negative (<10nM). Considering HA concentrations obtained for 
Immunotech EIA®, the area under the curve (AUC) was 0.990, and with a cut-off value of 
14.39nM (figure 4A), a sensitivity of 96.55% and a specificity of 97.06% was calculated. For 
LC-HRMS, the calculated AUC was 0.994 and the cut-off value was defined at 7.88nM with 
a sensitivity of 97.06% and a specificity of 98.28% (figure 4B). Using these new cut-offs and 
for the 92 tested samples, this allows minimizing the number of false positive samples from 
14 to 1 for Immunotech EIA, and reducing the number of false negative from 4 to 1 for LC-
HRMS (table 3). 
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4. CONCLUSION 
Our results demonstrate that LC-HRMS and Immunotech® EIA could be good alternatives to 
RIA for HA quantification in medical laboratories, after optimization of the sensitivity and the 
specificity of the two assays using new cut-offs (7.88 and 14.39nM for LC-HRMS and 
Immunotech® EIA, respectively). These two methods have the advantage to avoid the use of 
radioactivity with all its constraints. However, rare are the laboratories possessing a high-
resolution mass spectrometer due to the price of the instruments, and this could limit the 
development of HA quantification with LC-HRMS. 
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FIGURE LEGENDS 
Figure 1: Correlation and Bland-Altman analyses for Immunotech® EIA versus RIA for 
the quantification of histamine concentration in plasma samples. (A) Scatter plot of HA 
concentrations of the 72 plasma samples measured with Immunotech® EIA and RIA, and 
associated Pearson's correlation coefficient r. (B) Bland-Altman plot for Immunotech® EIA 
versus RIA. Y axis: 100*(EIA-RIA) / average]; X axis: average = (EIA + RIA)/2. (C) Scatter 
plot of HA concentrations of the 47 plasma samples presenting a concentration between 1 and 
20 nM by RIA, measured with Immunotech® EIA and RIA, and associated Pearson's 
correlation coefficient r.  
 
Figure 2: Correlation and Bland-Altman analyses for Demeditec Diagnostics® EIA 
versus RIA for the quantification of histamine concentration in plasma samples. (A) 
Scatter plot of HA concentrations of the 23 plasma samples measured with Demeditec EIA 
and RIA, and associated Pearson’s correlation coefficient r. (B) Bland-Altman plot for 
Demeditec Diagnostics® EIA versus RIA. Y axis: 100*(EIA-RIA) / average]; X axis: average 
= (EIA + RIA)/2.  
 
Figure 3: Correlation and Bland-Altman analyses for LC-HRMS versus RIA for the 
quantification of histamine concentration in plasma samples. (A) Scatter plot of HA 
concentrations of the 71 plasma samples measured with LC-HRMS and RIA, and associated 
Pearson's correlation coefficient r. (B) Bland-Altman plot for LC-HRMS versus RIA. Y axis: 
100*( LC-HRMS-RIA) / average]; X axis: average = (EIA + RIA)/2. (C) Scatter plot of HA 
concentrations of the 46 plasma samples presenting a concentration between 1 and 20 nM by 
RIA, measured with LC-HRMS and RIA, and associated Pearson's correlation coefficient r. 
 
Figure 4: Cut-off determination for the Immunotech® EIA and LC-HRMS method. 
Fifty-eight positive and 34 negative samples using a cut-off of 10 nM of histamine measured 
by RIA were used to build the ROC curves. The black arrows point the best cut-off values: 
14.39 nM and 7.88 nM were defined as the best cut-off values for Immunotech® EIA (A) and 
LC-HRMS (B), respectively. 
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Figure 2 
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Figure 3 
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Table 1: comparison of HA quantification in plasma samples analyzed by Immunotech® and 
Demeditec Diagnostics® EIA, LC-HRMS and RIA. (PPV: Positive Predictive Value, NPV: 
Negative Predictive Value) 
 RIA   
<10nM ?10nM Total 
 
Immunotech® 
EIA 
<10nM 20 
True negative 
0 
False negative 
20 NPV = 100% 
?10nM 14 
False positive 
58 
True positive 
72 PPV = 81% 
 Total 34 58 92  
 Sp = 59% Se = 100%  
 
 RIA   
<10nM ?10nM Total 
 
Demeditec 
Diagnostics® 
EIA 
<10nM 34 
True negative 
20 
False negative 
54 NPV = 63% 
?10nM 0 
False positive 
38 
True positive 
38 PPV = 100% 
 Total 34 58 92  
 Sp = 100% Se = 66%  
 
 RIA   
<10nM ?10nM Total 
 
 
LC-HRMS 
<10nM 34 
True negative 
4 
False negative 
38 NPV = 89% 
?10nM 0 
False positive 
54 
True positive 
54 PPV = 100% 
 Total 34 58 92  
 Sp = 100% Se = 93%  
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Table 2: Bias ± SD and 95% limits of agreement for HA quantification in plasma samples 
within the limits of detection of the methods, and focused on samples with a HA 
concentration measured by RIA comprised between 1 and 20nM. 
 Bias ? SD 95% limits of 
agreement 
Immunotech ® EIA vs RIA 3.10 ? 6.02 nM -8.69 - 14.90 nM 
Immunotech ® EIA vs RIA (1-
20nM) 
2.97 ? 3.08 nM -3.07 - 9.01 nM 
Demeditec ® EIA vs RIA -17.85 ? 20.16 nM -57.36 - 21.66 nM 
Demeditec ® EIA vs RIA (1-20nM)   
LC-HRMS vs RIA -5.52 ? 10.64 nM -26.36 - 15.33 nM 
LC-HRMS vs RIA (1-20nM) -1.94 ? 1.26 nM -4.41 - 0.53 nM 
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Table 3: comparison of HA concentrations in plasma samples quantified by Immunotech® 
EIA, LC-HRMS and RIA using optimized cut-offs. (PPV: Positive Predictive Value, NPV: 
Negative Predictive Value)  
 RIA   
<10nM ?10nM Total 
 
Immunotech® 
EIA 
<14.39 
nM 
33 
True 
negative 
2 
False 
negative 
35 NPV = 
97.06% 
?14.39 
nM 
1 
False positive 
56 
True positive 
57 PPV = 
98.25% 
 Total 34 58 92  
 Sp = 97.06% Se = 96.55%  
 
 RIA   
<10nM ?10nM Total 
 
 
LC-HRMS 
<7.88 nM 33 
True 
negative 
1 
False 
negative 
34 NPV = 
97.06% 
?7.88 nM 1 
False positive 
57 
True positive 
58 PPV = 
98.28% 
 Total 34 58 92  
 Sp = 98.28% Se = 97.06%  
 
 
